These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27993682)

  • 1. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
    Huynh FC; Nguyen D; Jones FE
    Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of S6K1 in ER-positive breast cancer.
    Holz MK
    Cell Cycle; 2012 Sep; 11(17):3159-65. PubMed ID: 22895181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1.
    Ben-Hur V; Denichenko P; Siegfried Z; Maimon A; Krainer A; Davidson B; Karni R
    Cell Rep; 2013 Jan; 3(1):103-15. PubMed ID: 23273915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.
    Huck B; Duss S; Hausser A; Olayioye MA
    J Biol Chem; 2014 Feb; 289(6):3138-47. PubMed ID: 24337579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
    Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
    Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
    Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
    Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Ghosh J; Kapur R
    Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J; Huang W
    PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
    Mohd Sharial MSN; Crown J; Hennessy BT
    Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells.
    Hirashita Y; Tsukamoto Y; Yanagihara K; Fumoto S; Hijiya N; Nakada C; Uchida T; Matsuura K; Kodama M; Okimoto T; Daa T; Seike M; Iha H; Shirao K; Murakami K; Moriyama M
    Cancer Sci; 2016 Dec; 107(12):1919-1928. PubMed ID: 27699948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
    Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
    Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation.
    Hong S; Zhao B; Lombard DB; Fingar DC; Inoki K
    J Biol Chem; 2014 May; 289(19):13132-41. PubMed ID: 24652283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
    Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
    Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling.
    Gao S; Duan C; Gao G; Wang X; Yang H
    Int J Biochem Cell Biol; 2015 Jul; 64():25-33. PubMed ID: 25813876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine does not affect mechanistic target of rapamycin complex 1 assembly but is required for maximal ribosomal protein s6 kinase 1 activity in human skeletal muscle following resistance exercise.
    Apró W; Moberg M; Hamilton DL; Ekblom B; Rooyackers O; Holmberg HC; Blomstrand E
    FASEB J; 2015 Oct; 29(10):4358-73. PubMed ID: 26169935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.